Message from Mr. Nicolas Sarkozy, President of the Republic, addressed to the participants of the Symposium on "Europe and Rare Diseases," on the national and European efforts to combat these diseases, October 10, 2008.

France Nicolas Sarkozy · President of France

10 October 2008 · Symposium on "Europe and Rare Diseases"

Context
Sarkozy addressed a European symposium on rare diseases on October 10, 2008, urging EU-level action and announcing a new French rare diseases plan.
Main themes
Rare diseases, European cooperation, French rare diseases plan, patient associations, clinical trials, EU presidency health priorities, research funding, reference centers, AFM and advocacy organizations
Duration
~3 min
7th percentile
Words
307
7th percentile
Sentences
18
9th percentile
Readability
52
70th percentile
Grade
10.2
23rd percentile
Syntax
2.65
10th percentile
Vocabulary
2.20
50th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 56%56%
  • Ceremonial 22%22%
  • Geopolitical 17%17%
  • Institutional 6%6%
  • Economic 0%0%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 0%

18 sentences in 6 paragraphs

Ladies and gentlemen,

I commend the initiative taken by the Rare Diseases Alliance and the French Association Against Myopathies to organize a European symposium on rare diseases. We need to bring together all forces to fight against these diseases. Today, after having come so far in France, we must take the fight to the European level. I am grateful to the associative world for once again paving the way.

For it is to you, actors in the associative world, that we owe the "rare diseases" plan of which our country can be proud. You were able, nearly twenty years ago, to transmit your communicative energy to researchers who have redoubled their efforts thanks to the additional resources you have generated. Today, thanks to you, we are embarking on the turning point of the first clinical trials on humans for certain rare diseases. This is a tremendous victory. This is your victory.

But, of course, the fight is far from over. As I committed myself, alongside Laurence TIENNOT-HERMENT, president of the AFM, the effort initiated under the rare diseases plan will continue. A new plan will be developed in 2009 and will come into effect by 2010 at the latest. The main achievements of the first plan—I am thinking particularly of the funding of reference centers—will be sustained.

Furthermore, I wish for the Commission's communication on the care of the 30 million Europeans affected by a rare disease to be one of the priorities of the French presidency of the European Union in the field of health. This communication must be followed by concrete actions. Europe must enable us to succeed where it can add value, for example in the field of information or research.

I hope that this symposium will be a success and a moment of unity around the cause of people affected by rare diseases.